- Research article
- Open Access
Discordance between clinical and immunological ART eligibility criteria for children in Malawi
© O’Hare et al.; licensee BioMed Central Ltd. 2014
- Received: 1 August 2013
- Accepted: 27 August 2014
- Published: 22 September 2014
Since May 2014, all HIV positive children aged less than five years in Malawi are eligible for ART. For children older than five years they are eligible if they are in WHO stage III/IV, if stage I/II, if their CD4 < 500 cells/mm3. Our goal was to compare the WHO clinical classification criteria (WHO stage + CD4/age) to CD4 count (CD4/age) on all children. Prior to 2014, children aged 2–5 years in stage I and II were eligible for ART if their CD4 was < 750 cells/mm3. We were interested in the increase in numbers of children in this age group who now meet the eligibility criteria and their average CD4 count.
Data including age, stage and CD4 count were used. We examined the effect of using two different criteria; WHO staging and checking CD4 count if stage I or II versus CD4 count on all, on the numbers of children eligibility for ART in a cohort of 969 children aged 0 to 14 years in Blantyre, Malawi.
Using WHO stage + CD4/age, 786 patients out of 969 would have been treated and 183 would not. Using CD4/age, 745 patients out of 969 would have been treated and 224 would not. Within the 224 patients not treated by CD4 classification, 41 were clinical stage III or IV. The most common staging condition in these 41 children was low weight for age (i.e. underweight). 41% of children age2-5 years have a CD4 count >750.
Most children are correctly started on treatment using recent guidelines. 41% more children <5 years will be started on ART.
- HIV treatment
- CD4 count
- WHO clinical staging
There are 35 million people living with Human Immunodeficiency Virus (HIV) in the world, 25 million of these live in Sub Saharan Africa (SSA) and about 10% are children . In the last decade the expansion of antiretroviral treatment (ART) in resource limited settings has resulted in eight million people receiving ART, and there were 39% fewer deaths from HIV in 2013 in SSA than in 2005 . However there are discrepancies between adults and children in terms of treatment coverage. It is estimated that 28% of children aged less than 15 who required ART were receiving it compared with 57% of adults . To facilitate the scale up of ART the World health Organization (WHO) have published sequential ART guidelines for a public health approach, the most recent being in 2013 . ART eligibility in children relies on both clinical and immunological criteria with the aim to start those who require ART with a minimum delay.
Malawian age adjusted thresholds for ART eligibility in children who are in WHO stage I/II
WHO 2006/Malawian 2008 guidelines
WHO 2010/Malawian 2011 guidelines
WHO 2013/Malawi 2014
< 12 months
12- 24 months
<20% or <750 cells/mm3
<20% or <750 cells/mm3
<15% or <350 cells/mm3
<15% or <250 cells/mm
Previous studies comparing clinical versus immunologic staging in children have demonstrated that agreement among eligibility criteria is poor. In a study in 2005 in Kinshasa, using WHO 2004 guidelines, 32.6% of children eligible by clinical criteria were not eligible according to immunological criteria (CD4, CD4% or total lymphocyte count) and 34.7% of children eligible on immunological criteria were not eligible by clinical criteria . A discrepancy was also observed in Tanzania, by Johnson et al., who reported that 22% of children who were staged as III/IV did not have severe immunosuppression using WHO 2006 definitions and 52% of children who were staged as stage I/II did have severe immunosuppression . Children who warrant treatment immunologically but who are not eligible using clinical staging alone represent a failure of the staging system. In view of reports of discrepancy, we wished to compare our current practise of determining eligibility by first staging our paediatric HIV antibody positive patients aged > 5 years and only carrying out a CD4 test on those in stage I and II with carrying out a CD4 test on all patients. We wished to evaluate if, by starting children who are staged as III/IV automatically, we were starting children earlier than they needed to be started, in a setting where the durability of ART regimes has not been fully determined and where we have no access to resistance testing in the case of ART failure. We were also interested in the specific categorizations that may inappropriately stage patients due to co-morbidities.
Guidelines on when to initiate ART in children in Malawi have evolved over time in line with WHO guidelines. National guidelines were published in 2008 and the pediatric component of these reflected the WHO 2006 guidelines . These were updated in 2011  and these largely reflected the 2010 WHO guidelines . The Malawian 2014 guidelines , based on the WHO 2013 guidelines , recommend starting all children aged < 5 years on ART and to use 500 cells/mm3 as the threshold for children older than five years. The trend has been towards starting children on ART with higher CD4 counts and towards using absolute numbers of CD4 cells rather than percentage of total lymphocyte counts. Current UK guidelines recommend that children aged < 1 year are universally started on ART but children > 1 year are started on age specific CD4 thresholds . The differences in the recommendations reflect a programmatic approach in countries with limited access to regular laboratory monitoring. We were also interested in the proportion of children who are now eligible by virtue of their age alone and what the average CD4 count of this group is. Our reason for interest in the average CD4 is that hypersensitivity reactions to nevirapine occur in children and are more common in patients with a higher CD4 count  and nevirapine is part of our first line regime.
In view of the 2014 guidelines, our first objective was to compare doing a clinical stage and carrying out a CD4 test on stage I and II in children >5 years versus the measurement of CD4 count on all patients > 5 years as a means to determine eligibility for ART in children.
In view of the recent change of guidelines we wished to look at the average CD4 of children aged 2–5 and the proportion of children in this age group who will automatically be started on ART but who would not have been eligible prior to the WHO 2013/Malawian 2014 guidelines, i.e. the proportion of children aged 2–5 with absolute CD4 counts >750 cells/mm3.
An observational cross sectional study on data routinely collected on all children enrolled for pre ART care between July 2010 and December 2012 was analyzed.
The nurse led pre ART clinic based at the Queen Elizabeth Central Hospital in Blantyre, Malawi. Children are referred to this clinic after their HIV diagnosis has been made from inpatient services and from surrounding urban clinics. HIV testing relies on two rapid tests for HIV-1 and HIV-2, Determine and Unigold (Determine; Abbott Laboratories, Abbott Park, Illinois, USA and Uni-Gold; Trinity Biotech, Bray, Ireland). The function of the clinic is to clinically stage the patients and to perform CD4 count. In September 2011, the Malawian Guidelines recommended that if a patient was staged as stage III or IV, they should not have a CD4 measured but rather start ART immediately. However, prior to this time a baseline CD4 was performed on all patients, therefore we have clinical staging data and CD4 results on patients in all WHO clinical stages. There is no user fee charged for this service and the clinic is open five days each week, morning and afternoon.
All Children aged between 0–14 years of age, from July 2010 and December 2012, who were seen in the pre ART at Queen Elizabeth Central Hospital were examined and staged by WHO criteria. Limited data were recorded, but those variables important for staging were noted. WHO clinical staging is routinely performed. The condition which resulted in them being assigned to a given stage was generally but not always recorded. CD4 counts are performed by the central laboratory at QECH using the Beckman Coulter Flow Care CD4 detection kit, and recorded in the database.
The study received ethical approval from the College of Medicine ethics committee (COMREC).
Name, age and date of birth if known, weight, height, Z score of weight for height, weight for age if < 5 years, clinical stage and CD4 count is collected for all patients attending the pre ART clinic.
CD4 counts on stage I and II versus CD4 counts on all – a comparison of two algorithms
Algorithm I – WHO stage + CD4/age
Algorithm II - CD4/age
Age < 5 TREAT
AGE < 5 = TREAT
Age > 5 Stage III or IV TREAT
Age > 5
Stage I or II
CD4 < 500 = TREAT
CD4 < 500 = TREAT
CD4 > 500 = Do not Treat
CD4 > 500 = Do not Treat
Clinical staging on all children >5 years and carry out a CD4 count on those in stage I and II, we call this WHO stage + CD4/age algorithm or algorithm 1.
The measurement of CD4 count on all children > 5 years, we call this cd4/age algorithm or algorithm 2.
We compared using Fisher’s Exact.
The distribution of patients by age category and WHO clinical stage
The median [IQR] age (in months) and absolute CD4 count for the four WHO clinical stages
Median age and IQR in months in each stage
The number of patients and median absolute CD4 count with IQR are shown by each of the classifications
CD4/Age (algorithm 2)
WHO stage, CD4 count (algorithm 1)
Total algorithm 1
Total algorithm 2
The 41 discordant treatment patients by age category and stage with median CD 4 counts and IQR given below
Children aged 2–5 eligible for ART on the WHO 2013/Malawian 2014 guidelines
Using the WHO 2013 guidelines, more children in our clinic qualify for ART treatment with the WHO + CD4/age classification than the CD4/age classification only. If patients were immunologically classified using CD4 counts and age only, there would have been 41 fewer children eligible for ART. These children were classified as Stage 3 or 4 but have CD4 counts > 500 cells/mm3. The most common clinical feature which resulted in children who had relatively high CD4 counts being classified as stage III/IV was weight for age below the 3rd centile i.e. underweight. Although all measures of anthropometric failure are more prevalent in HIV positive children , low weight for age is common in all Malawian children; 3- 5% of children aged < 5 years are severely underweight (weight for age is < − 3SD) . This may result in children being assigned to WHO stages III/IV despite a relatively good immune system. However the WHO 2013 guidelines results in the majority of children who would benefit from ART receiving it and only a small proportion who are not immunosuppressed starting earlier than required, mostly due to low weight for age.
Among the concerns of premature initiation of ART include the risk for adverse effects as well as resistance to first-line medications. However, this concern may be unfounded. The risk of adverse effects of ARVs and resistance to first-line medications was relatively low in a retrospective cohort study of 1434 Malawian children. Two percent of patients were on alternative first line treatment due to adverse effects and 1.5% were on second-line regimen due to ART failure after a median period on ART of 1.8 years . Five year survival of children on ART in this setting is 96% .
Our findings contrast with findings in the adult literature where more adults qualify for ARV treatment with CD4 classification than with the WHO classification. For example, a study in Uganda demonstrated that 53% of the patients in clinical stage I and II would have been eligible for ART with using CD4 counts < 250 cells/mm3 and 49% using CD4 counts < 350 cells/mm3. A study from Ghana found 29.5% of patients in stage I and II to have CD4 counts < 200 cells/mm3. In Malawian adults it was found that 25% of adults in stage I or II had CD4 counts < 250 cells/mm3 and 46% had CD4 counts < 350 cells/mm3.
41% in the 2–5 year age group would not have been eligible using the WHO 2010/Malawi 2011 guidelines are eligible for ART using the WHO 2013/Malawian 2014 guidelines. There is little clinical evidence to support early initiation of ART in children aged 2–5 years  and this is not current practice in the west , although it may be justified on a programmatic basis where there is limited access to CD4 counts .
Strengths and weakness of the study
This is a retrospective review of chart data which may contain some errors.
Strengths and weakness compared to other studies
The sample sizes in this study are larger than other studies and use the most recent guidelines.
The discordant rate is much lower than that reported by others and this is likely because we have used more recent guidelines for the modelling of our data [9, 10]. A weakness compared to other studies is the fact that the data was not collected prospectively .
Our current practise, based on the most recent guidelines, of clinically staging children, immediately starting all children in stage III and IV and doing CD4 counts on children who are found to be in stage I and II is likely to result in the majority of children being correctly started on treatment. Children who are staged as III or IV and who have a high CD4 count are likely to have been staged due to low weight for age. Treatment monitoring needs to take this into account and viral loads in cases of suspected failure should be done when a child on treatment is falling across centiles rather than low weight for age. The absence of a baseline CD4 in children who presented in stage III or IV means that immunological failure may be difficult to diagnose and ideally virological failure should be confirmed using viral load. The WHO 2013/Malawian 2014 guidelines will result in an increase in children aged 2–5 being started on ART and this will need to be monitored in terms of adverse effects as a result of starting children with high CD4s on ART and the known association between high CD4 and hypersensitivity when using nevirapine.
We would like to thank Sister Grace Matebule for her dedication to this group of children over many years.
- UNAIDS: Report on the global AIDS epidemic 2013 [Internet]. 2013, Available from: http://www.unaids.org/en/dataanalysis/knowyourepidemic/Google Scholar
- WHO/UNAIDS/UNICEF: Global Update on HIV Treatment. Results, Impact and Opportunities [Internet]. 2013, [cited 2014 Aug 10]. Available from: http://www.who.int/hiv/data/global_treatment_report_presentation_2013.pdfGoogle Scholar
- WHO HIV/AIDS programme: The use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013, Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdfGoogle Scholar
- Cross Continents Collaboration for Kids - Analysis and writing committee: Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008, 22 (1): 97-105. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18090397View ArticleGoogle Scholar
- Bamford A, Turkova A, Lyall EGH: PENTA guidelines for treatment of paediatric HIV-1 infection 2014: optimising health in preparation for adult life. 2014, PENTA steering committee, Available from: http://www.PENTA.orgGoogle Scholar
- Varughese JK, Rosenberg MG, Kim K: HIV in the tropics: staging in the resource-limited setting. Curr Opin Infect Dis. 2012, 25 (5): 477-483. 10.1097/QCO.0b013e3283567b00. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22744319PubMedView ArticleGoogle Scholar
- WHO HIV/AIDS Programme: Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access Recommendations for a Public Health Approach. 2006, Available from http://www.who.int/hiv/pub/guidelines/art/en/Google Scholar
- WHO HIV/AIDS Programme: Antiretroviral Therapy for HIV Infection Therapy for HIV Infection in Infants and Children. Towards Universal Access. 2010, Available from http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdfGoogle Scholar
- Callens SFJ, Kitetele F, Lusiama J, Shabani N, Edidi S, Colebunders R, Behets F, Van Rie A: Computed CD4 percentage as a low-cost method for determining pediatric antiretroviral treatment eligibility. BMC Infect Dis. 2008, 8: 31-10.1186/1471-2334-8-31.PubMedPubMed CentralView ArticleGoogle Scholar
- Johnson OO, Benjamin DK, Schimana W, Tillekeratne LG, Crump JA, Landman KZ, Kinabo GD, Mmbaga B, Msuya LJ, Shao JF, Swai ME, Cunningham CK: Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. Pediatr Infect Dis J. 2009, 28 (6): 493-497. 10.1097/INF.0b013e3181950b7f.PubMedPubMed CentralView ArticleGoogle Scholar
- Clinical management of HIV in children and adults - Malawian Integrated Guidelines for Providing HIV Services. 2011, Available from http://apps.who.int/medicinedocs/documents/s18802en/s18802en.pdf
- MOH Malawi: 2014 Clinical Management of HIV in Children and Adults Malawi Integrated Guidelines for Providing HIV Services in; 2014. ᅟ, Available from: http://cms.medcol.mw/cms_uploaded_resources/18381_16.pdfGoogle Scholar
- Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M, Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C, Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM: Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013, 381 (9875): 1391-1403.PubMedView ArticleGoogle Scholar
- Trehan I, O’Hare B, Phiri A, Heikens GT: Challenges in the management of HIV-infected malnourished children in Sub-Saharan Africa. AIDS Res Treat. 2012, 2012: 790786-PubMedPubMed CentralGoogle Scholar
- National Statistics Office: Demographic and Health Survey Malawi [Internet]. 2010, Available from: http://www.nsomalawi.mw/index.php/2010-malawi-demographic-and-health-survey-preliminary-report.htmlGoogle Scholar
- Buck WC, Kabue MM, Kazembe PN, Kline MW: Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc. 2010, 13: 31-10.1186/1758-2652-13-31.PubMedPubMed CentralView ArticleGoogle Scholar
- Baveewo S, Ssali F, Karamagi C, Kalyango JN, Hahn JA, Ekoru K, Mugyenyi P, Katabira E: Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda. PLoS One. 2011, 6 (5): e19089-10.1371/journal.pone.0019089.PubMedPubMed CentralView ArticleGoogle Scholar
- Torpey K, Lartey M, Amenyah R, Addo NA, Obeng-Baah J, Rahman Y, Suzuki C, Mukadi YD, Colebunders R: Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need?. Int J STD AIDS. 2009, 20 (6): 395-398. 10.1258/ijsa.2008.008333.PubMedView ArticleGoogle Scholar
- Lumala R, van den Akker T, Metcalf CA, Diggle E, Zamadenga B, Mbewa K, Akkeson A: CD4 testing at clinics to assess eligibility for antiretroviral therapy. Malawi Med J. 2012, 24 (2): 25-28.PubMedPubMed CentralGoogle Scholar
- Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old (Review). Cochrane Database Syst Rev. 2013, 10: CD010309-PubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.